From June 2017, the Office of Drug Control (ODC) sought comment from interested parties on the export of Australian cultivated and manufactured medicinal cannabis products.
The consultation process included seeking written submissions, holding two industry seminars on the regulatory scheme (including discussing the proposal for export) and hosting over a dozen private industry meetings on narcotic drug licencing and export related issues. Written submissions closed on the 21 July 2017.
Over 40 written submissions were received from a variety of private companies (incorporating pharmaceutical manufacture companies, cultivators and manufacturers), professional associations, consultancies and individuals.
Click here for the results of the consultation.